Research for HerTM, an online clinical research registry, honored with distinguished national award

January 14, 2014

LOS ANGELES (Jan. 14, 2014) - Research for HerTM , a Cedars-Sinai online medical research database aimed at increasing women's participation in clinical studies, received the 2013 Award for Excellence from the Health Improvement Institute for its user-friendly electronic consent form.

The Research for Her registry allows women to register for potential participation in clinical trials through an online, verified consent process that is just two pages long and written in nontechnical, easy-to-understand language. In comparison, a typical clinical trial consent form, even for low-risk clinical trials, is a printed document ranging from eight to 15 pages and includes complex medical and legal terminology.

"By listening to the new ideas and barriers of our target population, we were able to respond and adapt to better meet the needs of women in the community," said Beth Y. Karlan, MD, director of the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, director in the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, director of the Gilda Radner Hereditary Cancer Program and the Board of Governors Chair in Gynecologic Oncology. "Women have responded affirmatively and we have more than quadrupled the monthly enrollment average in our clinical trials. The hope is for this template to become standard practice for low-risk clinical trial enrollment across the nation and to bolster women's access to cutting-edge clinical studies."

Research for Her was awarded the 2013 Award for Excellence in Human Research Protection for Best Practice from the Health Improvement Institute because of Cedars-Sinai's commitment to developing practices that safeguard the safety and welfare of research participants while keeping up with modern technology and lifestyles.

"Online consenting is not only sustainable, it is vital to the growth of research programs, such as Research for Her," said Eifaang Li, director of the Office of Research Compliance and Quality Improvement at Cedars-Sinai. "Utilizing technology allows the program to not only reduce the time patients spend in the clinic, but also increase operational efficiency. Online consenting also allows the Research for Her program to stay up to date in an increasingly technological society."

Historically, relatively few women have participated in clinical research, and as a result, the medical science community has often ignored biological differences between men and women. Research for Her, a partnership with the Samuel Oschin Comprehensive Cancer Institute, the S. Mark Taper Foundation Imaging Center and the Cardio-Oncology Program, aims to improve the involvement of women in clinical trials and register women with or without a history of breast or gynecologic cancers.

As the Research for Her program continues to advance, approved investigators will review the collected information and identify opportunities to improve care for women with cancer risk factors and those who are at high risk for other diseases. The registry will also help identify subjects who may be eligible for research studies, including large-scale epidemiological studies, cancer screening studies, focus groups and clinical therapeutic trials. Research for Her study participants will then be contacted by Cedars-Sinai investigators to gauge enrollment interest and eligibility.

Co-principal investigator BJ Rimel, MD, a gynecologic oncologist in the Department of Obstetrics and Gynecology at Cedars-Sinai, said nearly 300 of the more-than 535 women who have consented in the lifetime of the registry did so online. Many of these participants have been linked to several studies. To participate in Research for Her, please click here.

"This award piggybacks on Cedars-Sinai's institutional commitment to providing excellent clinical and service quality, offering compassionate care and supporting research and medical education, while also responding to patient needs," said Karlan.
-end-


Cedars-Sinai Medical Center

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.